The U.S. Supreme Court declined to hear appeals from several pharmaceutical companies challenging Medicare's drug price negotiation program, a setback for brand-name drugmakers. The White House also expanded its TrumpRx platform by adding over 600 generic drugs through partnerships with Amazon Pharmacy and GoodRx, addressing previous criticisms about limited offerings.
This development could restrict future legal challenges against the Medicare drug pricing initiative and enhance patient access to affordable generics via expanded discount platforms.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
15
Ali NematiWritten by Ali
